Following an extensive five-hour debate, the South Carolina House of Representatives granted second reading approval to a bill that reclassifies common abortion medications as controlled substances. The legislation aims to criminalize the distribution of these drugs when obtained through online services or from out-of-state providers.
The bill designates medications like mifepristone and misoprostol as Schedule IV controlled substances. This classification places the drugs in the same regulatory category as substances like Xanax and Valium, which are deemed to have a lower risk of addiction but require strict oversight.
Closing Telehealth Gaps
Proponents of the measure argue that the reclassification is necessary to close a legal loophole that allows residents to circumvent the state’s existing six-week abortion ban. Currently, individuals can receive these medications via mail after virtual consultations with out-of-state physicians.
Legislators supporting the bill maintain that requiring in-person exams and prescriptions from South Carolina-licensed doctors ensures medical quality and safety. Under the proposed law, while pregnant women remain exempt from prosecution, those who knowingly mail, distribute, or transport the drugs into the state could face felony charges and imprisonment.
Concerns Over Medical Access
Opponents and medical professionals expressed concern during the floor debate that the bill could hinder access to drugs used for non-abortion purposes. These medications are frequently utilized for miscarriage management, treating hemorrhages, and other reproductive health conditions.
Critics argued that mifepristone and misoprostol show no history of abuse or addiction, suggesting that a Schedule IV designation is medically unnecessary and could create administrative delays in emergency hospital settings.
Legislative Path Forward
The House is expected to provide final approval for the bill on Thursday, Feb. 5, 2026. If passed, the legislation will move to the State Senate for further consideration. While Senate leadership has previously expressed concerns regarding medication abortion, it remains uncertain if the chamber will prioritize the measure before the current session concludes in May.
Sign up for our Sunday Spectator. Delivered to your inbox every Sunday, with all the news from the week.
